title: Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy.
abstract: Fibrates, the ligands of peroxisome proliferator-activated receptor-alpha, have been shown to have a renal protective action in diabetic models of renal disease, but the mechanisms underlying this effect are unknown. In the present study, we sought to investigate in greater detail the effect of fenofibrate and its mechanism of action on renal inflammation and tubulointerstitial fibrosis in an animal model of type 2 diabetes mellitus. Twelve-week-old non-diabetic Zucker lean (ZL) and Zucker diabetic fatty (ZD) rats were treated with vehicle or fenofibrate for 10 weeks. mRNA and protein analyses were performed by real-time polymerase chain reaction, Western blot and immunostaining. The diabetic condition of ZD rats was associated with an increase in collagen and alpha-smooth muscle actin accumulation in the kidney, which was significantly reduced by fenofibrate. Chronic treatment of ZD rats with fenofibrate attenuated renal inflammation and tubular injury as evidenced by a decrease in mRNA and protein expression of secreted phosphoprotein-1, monocyte chemotactic protein-1 and kidney injury molecule-1 in the kidneys. Renal interstitial macrophage infiltration was also significantly reduced in the kidneys of fenofibrate-treated diabetic animals. Moreover, renal nuclear factor (NF)-kappaB DNA-binding activity, transforming growth factor (TGF)-beta1 and phospho-Smad3 proteins were significantly higher in ZD animals compared with ZL ones. This increase in NF-kappaB activity, TGF-beta1 expression and Smad3 phosphorylation was greatly attenuated by fenofibrate in the diabetic kidneys. Taken together, fenofibrate suppressed NF-kappaB and TGF-beta1/Smad3 signaling pathways and reduced renal inflammation and tubulointerstitial fibrosis in diabetic ZD animals.
authors.affiliation: Department of Physiology, Atlanta, GA 30310, USA.
authors.forename: Lingyun
authors.initials: L
authors.lastname: Li
authors.forename: Nerimiah
authors.initials: N
authors.lastname: Emmett
authors.forename: David
authors.initials: D
authors.lastname: Mann
authors.forename: Xueying
authors.initials: X
authors.lastname: Zhao
mesh_terms: D000199:Actins / Q000378:metabolism; D000818:Animals; D003094:Collagen / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000473:pathology*; D011345:Fenofibrate / Q000494:pharmacology*; D005355:Fibrosis; D000960:Hypolipidemic Agents / Q000494:pharmacology; D007249:Inflammation / Q000188:drug therapy; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D009130:Muscle, Smooth / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism*; D051381:Rats; D011924:Rats, Zucker; D051900:Smad3 Protein / Q000037:antagonists & inhibitors / Q000378:metabolism*; D053773:Transforming Growth Factor beta1 / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D000199:Actins; D000960:Hypolipidemic Agents; D016328:NF-kappa B; D051900:Smad3 Protein; C497787:Smad3 protein, rat; D053773:Transforming Growth Factor beta1; D003094:Collagen; D011345:Fenofibrate
references.citation: Kidney Int. 2003 Jan;63(1):209-16
references.pmid: 12472785
references.citation: Antioxid Redox Signal. 2002 Dec;4(6):877-84
references.pmid: 12573136
references.citation: Clin Chem. 2008 May;54(5):814-23
references.pmid: 18339698
references.citation: J Biol Chem. 2008 Oct 24;283(43):29109-18
references.pmid: 18701451
references.citation: Hypertension. 2009 Oct;54(4):877-84
references.pmid: 19667256
references.citation: APMIS. 1992 Mar;100(3):256-68
references.pmid: 1562318
references.citation: Eur J Clin Invest. 2000 Oct;30(10):871-8
references.pmid: 11029601
references.citation: Nephron. 1998;79(1):33-7
references.pmid: 9609459
references.citation: J Am Soc Nephrol. 1996 Dec;7(12):2604-15
references.pmid: 8989739
references.citation: Nephrol Dial Transplant. 2009 Nov;24(11):3265-8
references.pmid: 19318357
references.citation: Pharmacotherapy. 2007 Mar;27(3):412-24
references.pmid: 17316152
references.citation: Am J Physiol Renal Physiol. 2002 Dec;283(6):F1326-36
references.pmid: 12388382
references.citation: Mol Pharmacol. 2007 Nov;72(5):1238-45
references.pmid: 17671096
references.citation: Kidney Int. 2007 Mar;71(5):417-24
references.pmid: 17213874
references.citation: J Am Soc Nephrol. 2002 Apr;13(4):894-902
references.pmid: 11912248
references.citation: FEBS Lett. 2008 Jun 18;582(14):2051-65
references.pmid: 18375206
references.citation: Clin Exp Nephrol. 2006 Sep;10(3):186-92
references.pmid: 17009076
references.citation: Exp Mol Med. 2009 Jun 30;41(6):397-405
references.pmid: 19322024
references.citation: Diabetes. 2000 Mar;49(3):466-75
references.pmid: 10868970
references.citation: Diabetes. 1994 Aug;43(8):1046-51
references.pmid: 8039599
references.citation: Diabetes. 2006 Apr;55(4):885-93
references.pmid: 16567507
references.citation: J Clin Pathol. 1996 Oct;49(10):783-6
references.pmid: 8943739
references.citation: Nephrol Dial Transplant. 2004 Dec;19(12):2987-96
references.pmid: 15574996
references.citation: Mol Ther. 2001 Feb;3(2):149-59
references.pmid: 11237671
references.citation: Drugs. 2007;67(1):121-53
references.pmid: 17209672
references.citation: Kidney Int. 2004 Aug;66(2):597-604
references.pmid: 15253712
references.citation: Kidney Int. 1995 Aug;48(2):439-48
references.pmid: 7564111
references.citation: Kidney Int. 2008 Aug;74(4):413-5
references.pmid: 18670406
references.citation: Kidney Int Suppl. 1994 Nov;47:S101-4
references.pmid: 7869656
references.citation: Diabetologia. 1998 Feb;41(2):185-92
references.pmid: 9498652
references.citation: J Am Soc Nephrol. 2004 Aug;15(8):2139-51
references.pmid: 15284299
references.citation: J Am Soc Nephrol. 2008 Sep;19(9):1672-80
references.pmid: 18508967
references.citation: Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):307-13
references.pmid: 12588776
references.citation: Am J Physiol Renal Physiol. 2008 Apr;294(4):F697-701
references.pmid: 18272603
references.citation: J Pharmacol Exp Ther. 2008 Feb;324(2):658-63
references.pmid: 17993607
references.citation: Am J Cardiol. 2007 Jun 18;99(12A):56i-67i
references.pmid: 17599426
references.citation: J Exp Med. 2005 Dec 19;202(12):1659-68
references.pmid: 16352738
references.citation: Histol Histopathol. 2008 Jun;23(6):731-9
references.pmid: 18366011
references.citation: J Biol Chem. 2000 Sep 15;275(37):28937-46
references.pmid: 10874048
references.citation: Metabolism. 2008 Nov;57(11):1516-25
references.pmid: 18940388
references.citation: J Biol Chem. 2002 Oct 18;277(42):39739-48
references.pmid: 12138159
references.citation: Kidney Int. 2006 Jan;69(1):73-80
references.pmid: 16374426
references.citation: Kidney Int. 2006 May;69(9):1511-7
references.pmid: 16672921
references.citation: Am J Kidney Dis. 2009 Jan;53(1):16-25
references.pmid: 18823687
references.citation: Am J Physiol Renal Physiol. 2006 Aug;291(2):F456-64
references.pmid: 16467126
references.citation: J Am Soc Nephrol. 2004 May;15(5):1244-53
references.pmid: 15100364
references.citation: Kidney Int. 2007 Jul;72(2):193-201
references.pmid: 17507908
references.citation: Am J Kidney Dis. 2005 Mar;45(3):485-93
references.pmid: 15754270
references.citation: Am J Physiol Renal Physiol. 2007 Jan;292(1):F313-20
references.pmid: 16896183
references.citation: Am J Nephrol. 2008;28(4):598-606
references.pmid: 18277067
references.citation: J Intern Med. 2002 Jun;251(6):490-9
references.pmid: 12028504
references.citation: Vascul Pharmacol. 2006 May;44(5):309-15
references.pmid: 16624630
references.citation: Nephrol Dial Transplant. 2004 Feb;19(2):277-81
references.pmid: 14736944
references.citation: Clin J Am Soc Nephrol. 2006 Sep;1(5):1090-9
references.pmid: 17699330
references.citation: Trends Biochem Sci. 2004 May;29(5):265-73
references.pmid: 15130563
references.citation: Mol Cell Biochem. 2000 Apr;207(1-2):123-9
references.pmid: 10888237
references.citation: Am J Physiol Renal Physiol. 2009 May;296(5):F1136-45
references.pmid: 19225054